Core Viewpoint - Multiple myeloma, the second most common hematological malignancy, poses significant treatment challenges due to its incurable nature and high relapse rates, but advancements in medical technology have led to innovative therapies that offer hope for "functional cure" and improved quality of life for patients [1][8]. Group 1: Disease Overview - Multiple myeloma is characterized by malignant proliferation of plasma cells, which are crucial for immune function, leading to the production of ineffective immunoglobulins that harm normal bodily functions [3][4]. - The disease's early symptoms are often non-specific, leading to misdiagnosis, with common symptoms summarized by the "CRAB" acronym: hypercalcemia, renal impairment, anemia, and bone lesions [3][4]. Group 2: Diagnosis and Monitoring - Patients often seek treatment for symptoms like renal issues or bone pain, mistakenly attributing them to other conditions, which can delay diagnosis and worsen outcomes [4][5]. - Monitoring serum protein levels is critical, with levels exceeding 50 g/L warranting further investigation for multiple myeloma [4]. Group 3: Treatment Approaches - Treatment for multiple myeloma is individualized, with options including traditional chemotherapy, targeted therapy, immunotherapy, and stem cell transplantation, depending on patient-specific factors [7][9]. - Recent advancements have introduced bispecific antibodies as a standard treatment for relapsed/refractory multiple myeloma, showing efficacy rates over 60% and complete response rates around 35% [9]. Group 4: Prognosis and Future Directions - The five-year survival rate for multiple myeloma patients has improved significantly, with many now living for over a decade, thanks to new therapies [8][9]. - The concept of "functional cure" is emerging, where patients may have residual tumor cells that are undetectable and coexist with the immune system, allowing for a normal quality of life [9].

消息面上，8月6日早盘，舒泰神股价在5分钟内快速回调，跌幅超过2%。 资金流向方面，8月6日主力资金净流出3420.89万元，近五日累计净流出4.12亿元。 风险提示：股市有风险，投资需谨慎。 截至2025年8月6日收盘，舒泰神股价报48.76元，较前一交易日下跌1.32元，跌幅2.64%。盘中最高触及 52.37元，最低下探47.60元，振幅达9.52%。当日成交量为21.33万手，成交额10.63亿元，换手率为 4.52%。 舒泰神属于生物制品行业，业务涵盖创新药研发及生产，主要产品包括单抗类药物。公司总部位于北 京，是创业板上市企业。 ...